Lineage Cell Therapeutics

Update in progress

LCTX (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on cell replacement therapies for serious conditions in the U.S. and globally. Its programs include OpRegen, an allogeneic retinal pigment epithelium therapy in Phase 2a for age-related macular degeneration; OPC1, allogeneic oligodendrocyte progenitor cells in Phase 1/2a for cervical spinal cord injury; and several preclinical and exploratory programs. The company collaborates with William Demant Invest and Factor Bioscience, formerly known as BioTime, Inc., founded in 1990 and headquartered in Carlsbad, California.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive